Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:16 AM
Ignite Modification Date:
2025-12-25 @ 2:16 AM
NCT ID:
NCT07034560
Eligibility Criteria:
Inclusion Criteria:
1. Patients with the age above 18 years and above
2. Patients diagnosed with epidermal or mixed-type melasma
Exclusion Criteria:
1. Use of topical medications such as hydroquinone, whitening agents (e.g., arbutin, kojic acid, vitamin C, retinoids, and steroids) on melasma areas within 4 weeks prior to joining the study
2. Chemical peeling within 4 weeks prior to joining the study
3. Use of oral tranexamic acid or any supplements within 3 months prior to joining the study
4. History of laser treatment, dermabrasion, or skin-tightening devices within 6 months prior to joining the study
5. History of botulinum toxin injections, fillers, collagen stimulators, or thread lifts within 12 months prior to joining the study
6. Pregnancy or breastfeeding
7. Use of hormonal contraceptives within 1 year prior to joining the study
8. Personal or family history of thrombotic disorders, such as deep vein thrombosis, pulmonary embolism, stroke, protein C or S deficiency, or antithrombin III deficiency
9. History of more than 2 spontaneous abortion
10. History of impaired kidney function
11. History of cancer
12. Smoking
13. Heart disease (e.g., end-stage heart failure, chronic obstructive pulmonary disease, or use of prosthetic heart valves)
14. History of allergy to oral tranexamic acid or melatonin
15. Patients who are unable to follow up as per the study protocol
16. Patients with Hori's nevus
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT07034560
Study Brief:
Protocol Section:
NCT07034560